ADHD Research & Healthcare
ADHD is increasingly recognised as a condition that can have significant consequences for health, wellbeing and everyday life. Recent research into mortality, alongside major reviews of NHS ADHD services, is prompting important questions about how people should access assessment, medication and ongoing care.
The debate surrounding ADHD in England has often focused on rising diagnosis rates, long waiting lists and concerns about private healthcare providers. However, these discussions can overlook a more important question: are people with ADHD receiving timely, effective and clinically appropriate care? Recent evidence suggests that the consequences of untreated or inadequately supported ADHD may extend far beyond difficulties with concentration, organisation or impulsivity. At the same time, national reviews are exploring how ADHD services could become more accessible, better integrated with other healthcare services and more responsive to individual needs. Together, these developments offer an opportunity to rethink ADHD care without compromising diagnostic standards or restricting access to effective treatment.
ADHD and mortality: Why this research matters
Research examining mortality among people with ADHD has identified associations between ADHD and an increased risk of several serious health outcomes.
A systematic review and meta-analysis reported approximately 1.7 times the risk of all-cause mortality among people with ADHD, alongside elevated risks of suicide, injury and natural-cause mortality. The estimates varied between studies and outcomes. These findings challenge the perception that ADHD is simply a difficulty with concentration or organisation. ADHD can affect decision-making, emotional regulation, impulse control and the ability to manage everyday responsibilities. For some individuals, these difficulties may contribute to vulnerability across several areas of health and wellbeing.
However, it is important to interpret the evidence carefully. An association between ADHD and increased mortality does not mean that ADHD directly causes every adverse outcome. Coexisting mental and physical health conditions, socioeconomic circumstances, access to healthcare and other factors may contribute to the observed differences. The findings nevertheless reinforce the importance of recognising ADHD as a condition that can have substantial clinical and functional consequences.
ADHD is more than a difficulty with attention. Research suggests it can be associated with significant long-term health risks, reinforcing the importance of appropriate assessment and care.
Is ADHD medication associated with better long-term outcomes?
Research has also examined whether ADHD medication is associated with differences in mortality.
Large observational studies have reported associations between ADHD medication use and lower all-cause mortality. Some findings suggest that treatment may be particularly relevant to outcomes involving injury and other preventable risks. This is encouraging, but observational research cannot establish that medication itself causes a reduction in mortality. People receiving treatment may differ from untreated individuals in several important ways, including healthcare access, clinical monitoring, treatment adherence and other health-related factors.
Nevertheless, the evidence adds to the wider understanding of why access to appropriate ADHD treatment matters. Medication can improve core ADHD symptoms for many individuals and may support functioning in education, employment, relationships and everyday activities. It is not suitable for everyone, and treatment decisions should always consider individual preferences, potential benefits, adverse effects and relevant physical and mental health conditions. The aim should not be to prescribe medication indiscriminately, but to ensure that people who may benefit from treatment are able to access a comprehensive assessment and make informed decisions about their care.
The NHS ADHD Taskforce: Rethinking how ADHD services work
The independent NHS England ADHD Taskforce published its reports in 2025, setting out recommendations for improving the recognition, assessment and management of ADHD.
The Taskforce highlighted substantial difficulties within existing services, including long waiting lists, fragmented pathways and inconsistent access to support. An important theme was the need to move beyond a system in which practical help is often dependent on first obtaining a formal diagnosis. Children, young people and adults may experience significant difficulties with education, employment, relationships or everyday functioning while waiting for assessment. Support with these needs should not always have to wait until the diagnostic process has been completed.
However, needs-led support should complement rather than replace specialist diagnostic assessment. A formal diagnosis remains important when determining appropriate treatment, understanding coexisting conditions and considering medication. The Taskforce also emphasised the importance of developing ADHD knowledge across a wider range of healthcare professionals and improving coordination between primary care, specialist services and other agencies. These recommendations recognise that ADHD is not solely a specialist psychiatric issue. Its effects can extend across physical health, mental health, education, employment and family life.
The Fonagy review: Protecting access to appropriate treatment
The October 2026 independent review into mental health conditions, ADHD and autism, chaired by Professor Peter Fonagy, added further recommendations concerning the assessment and treatment of neurodevelopmental conditions.
An important message was the need to maintain access to ADHD medication for people who meet diagnostic criteria and experience clinically significant impairment. The review also highlighted the importance of reducing treatment gaps, strengthening prescribing governance and ensuring that medication is delivered within comprehensive care pathways. These recommendations are particularly relevant given the public debate about whether ADHD is being overdiagnosed. Rising referral numbers do not, in themselves, establish that ADHD is being diagnosed incorrectly. Increased recognition, greater public awareness and longstanding unmet need may all contribute to demand.
At the same time, high-quality assessment remains essential. Both underdiagnosis and misdiagnosis can occur, and services must be able to distinguish ADHD from other conditions that may produce overlapping difficulties. Treatment decisions should therefore be based on individual clinical need and robust assessment rather than assumptions about diagnosis rates across the population. For people already benefiting from medication, continuity of care is also important. Decisions about treatment should consider effectiveness, tolerability, physical health and individual circumstances rather than being driven solely by changes in service organisation.
Treatment decisions should be guided by individual clinical need, not generalised concerns about rising ADHD diagnosis rates.
Could more ADHD care be delivered through primary care?
One approach being explored is the development of more integrated ADHD services within primary care, supported by specialist pathways for people with additional or complex needs.
Under this type of model, individuals could receive an initial assessment of their difficulties and access practical support without necessarily waiting for a specialist diagnostic appointment. Some people might benefit from structured self-management resources, psychoeducation or support with everyday functioning. Others would require further diagnostic assessment, medication or specialist mental health input. Digital systems could help improve communication, reduce duplication and support the transfer of relevant clinical information between services.
There are potential benefits to this approach. Primary care is often more accessible than specialist services and may already have an established understanding of a person's medical history and wider circumstances.
However, moving ADHD care into primary care requires appropriate training, resources, prescribing arrangements and access to specialist advice. It should not simply transfer additional responsibilities to already stretched GP practices. Crucially, a needs-led approach must not become a mechanism for delaying or restricting access to diagnostic assessment or medication when these are clinically indicated. These models remain proposals for service development rather than a single established national pathway.
Not everyone with ADHD needs the same level of specialist care
Another important consideration is how services respond to differences in clinical complexity.
Some adults with ADHD have relatively stable presentations, lower levels of clinical risk and coexisting health conditions that can be managed effectively within primary care. Others may require more specialist involvement because of significant diagnostic uncertainty, severe mental illness, current safeguarding concerns, complex substance dependence or substantial risks to themselves or others.
However, complexity should never be determined simply by the presence of another diagnosis. An adult with ADHD and autism may have relatively straightforward treatment needs, while someone with ADHD alone may experience significant functional impairment requiring specialist support.
Similarly, anxiety or depression does not automatically mean that an individual requires secondary mental health services. The appropriate level of care should reflect the person's overall presentation, risks, treatment needs and circumstances, rather than a rigid list of diagnoses. This individualised approach is consistent with the wider aim of providing proportionate, accessible and clinically appropriate ADHD care.
Why ADHD and mental health services need to work together
ADHD frequently coexists with other mental health and neurodevelopmental conditions.
Some adults experience anxiety, depression, autism, eating difficulties, substance misuse or other mental health needs alongside ADHD. These conditions may influence how ADHD presents, how symptoms are experienced and which treatments are appropriate. Historically, separate diagnostic pathways have sometimes made it difficult for people to access coordinated care. Someone may be referred between services because their presentation does not fit neatly within a single diagnostic category. Others may receive treatment for one condition while their ADHD remains unrecognised.
Better integration between ADHD services, community mental health teams, primary care and other specialist services could help address these difficulties. For example, an adult with ADHD and a significant eating disorder may require coordinated treatment involving both areas of expertise. Another person with ADHD and stable anxiety may be appropriately supported through a combination of ADHD treatment and primary care. The objective should be to recognise the whole person rather than expecting individuals to navigate multiple disconnected services.
Private ADHD providers: The importance of distinguishing different models of care
The rapid expansion of independent ADHD services has attracted increasing attention, particularly where private companies are delivering NHS-funded assessments and treatment. Research published by the Centre for Health and the Public Interest has raised concerns about NHS expenditure on independent ADHD providers, the growth of commercially operated services, contracting arrangements and the need for stronger regulatory oversight. These concerns are important, particularly when public funding is used to commission services from external organisations.
However, the term private ADHD provider encompasses a wide range of organisations operating under very different business models. There is a substantial distinction between a large, investor-backed healthcare company delivering high volumes of NHS-funded assessments and a small, clinician-owned independent practice providing directly funded care to individual patients.
These differences matter when considering financial incentives, accountability and the relationship between independent healthcare and NHS resources.
Independent, clinician-led care at Juno Clinic
Juno Clinic is a small, specialist nurse-led adult ADHD service in South Manchester. It operates as an independent clinical practice rather than a private-equity-backed healthcare organisation. Our approach is based on professional clinical practice, individualised assessment and continuity of care, rather than a high-volume model of NHS-funded assessments.
Juno Clinic is not funded by private equity, and our privately funded assessment model does not involve receiving NHS commissioning payments for those assessments. This is an important distinction when discussing concerns about commercial organisations receiving substantial amounts of NHS funding.
However, independent healthcare providers still have responsibilities to ensure that their services are clinically appropriate, transparent and accountable. A provider's ownership structure does not, by itself, establish the quality of its assessments.
At Juno Clinic, the focus is on comprehensive assessment, careful consideration of diagnostic criteria, identification of coexisting conditions and appropriate treatment planning. As a specialist nurse-led service, clinical decisions are grounded in professional accountability, NICE guidance and the individual needs of each patient.
Find out more: junoclinic.co.uk
What should high-quality ADHD care look like?
The emerging evidence and national recommendations point towards several important principles. People experiencing clinically significant ADHD symptoms should have timely access to comprehensive assessment. Support with everyday difficulties should be available where possible before diagnosis, but should not replace access to appropriate diagnostic services. Treatment should be individualised and may include medication, psychoeducation, environmental adjustments, psychological interventions and practical strategies.
Where medication is prescribed, appropriate baseline assessment, titration, physical health monitoring and ongoing review are essential. Services should also recognise that ADHD frequently coexists with other conditions and that people may require different levels of support at different stages of their lives.
Finally, clinical standards should be consistent across NHS and independent services. The professional competence of the assessor, the quality of the assessment and the safety of ongoing care should matter more than whether the service is publicly or privately operated.
The future of ADHD care in England
The direction of current research and policy is increasingly clear: ADHD should be recognised as a condition that can have substantial consequences for health and everyday functioning, and services must become more accessible, integrated and responsive to individual need.
The evidence surrounding mortality reinforces the importance of taking ADHD seriously, while research into medication outcomes highlights the potential value of appropriate treatment. The NHS ADHD Taskforce and Fonagy review also suggest that improving services will require more than increasing diagnostic capacity. Better coordination, workforce development, prescribing governance and support across different levels of healthcare will be essential.
However, these changes must be implemented carefully. Expanding access should not come at the expense of diagnostic quality, and introducing needs-led pathways should not create new obstacles for people requiring specialist assessment or medication.
The challenge for the future is not simply to diagnose more people or reduce waiting lists, but to ensure that people with ADHD receive the right support, at the right time, from appropriately qualified healthcare professionals.
References and further reading
- Mortality Among People With Attention-Deficit/ Hyperactivity Disorder: A Systematic Review and Meta-Analysis. JAMA Network Open (2026). Research examining associations between ADHD and mortality across different causes of death. Read the study
- NHS England. Independent ADHD Taskforce: Part 1 (2025). Recommendations concerning ADHD recognition, assessment, unmet need and support. Read the report
- NHS England. Independent ADHD Taskforce: Part 2 (2025). Further recommendations concerning service development, workforce competencies and integrated ADHD care. Read the report
- Department of Health and Social Care. Independent Review into Mental Health Conditions, ADHD and Autism: Final Report (October 2026). Recommendations concerning support, diagnostic services and access to appropriate treatment. Read the report
- Centre for Health and the Public Interest. Market Failure: How the Under-Regulated Market in NHS-Funded ADHD Services Impacts Patients and the Finances of the NHS (2026). Analysis of commissioning, financing and regulation of NHS-funded independent ADHD services. Visit CHPI
- NICE. Attention Deficit Hyperactivity Disorder: Diagnosis and Management (NG87). Clinical recommendations concerning ADHD assessment, diagnosis, medication and monitoring. Read NICE guidance
- Nursing and Midwifery Council. The Code. Professional standards of practice and behaviour for registered nurses. Read the NMC Code
This article provides general information about ADHD research and healthcare policy. The mortality findings are associations and should not be interpreted as proof of causation. Proposed service models are discussed as potential developments rather than established national arrangements.